Adipocytokine profiles as influenced by insulin resistance in obese subjects

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 3, Issue 2, 2009, Pages 79-83

  Al Daghri, Nasser M ^a   Al Attas, Omar S ^a   Sallam, Reem ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Adipocytokines; Adiponectin; Insulin resistance; Leptin; Obese; Resistin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SAUDI ARABIA; SEX DIFFERENCE;

EID: 67349115190     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2009.02.004     Document Type: Article

References (49)

1. Thourani V.H., Weintraub W.S., Stein B., Gebhart S.S., Craver J.M., Jones E.L., et al. Influence of diabetes mellitus on early and late outcomes after coronary artery bypass grafting. Ann Thorac Surg 67 (1999) 1045-1052
2. Groop L.C., Saloranta C., Shank M., Bonadonna R.C., Ferrannini E., and DeFronzo R.A. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72 (1991) 96-107
3. McTernan P.G., Fisher F.M., Valsamakis G., McTernan C.L., Chetty R., Harte A., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88 (2003) 6098-6106
4. Harte A.L., McTernan P.G., Matyka K., McTernan C.L., Crocker J., Barnett A.H., et al. Insulin increases angiotensinogen expression in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 5 (2003) 462-467
5. Harte A.L., McTernan P.G., McTernan C.L., Smith S.A., Barnett A.H., and Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 5 (2003) 302-310 5
6. Valsamakis G., Chetty R., McTernan P.G., Al-Daghri N., Jones A., and Kumar S. Fasting serum adiponectin concentration is reduced in Indo-Asians and is related to HDL cholesterol. Diabetes Obes Metab 5 (2003) 131-135
7. McTernan P.G., Harte A.L., Anderson L.A., Green A., Holder J., Smith S.A., et al. Long-term insulin and rosiglitazone mediated regulation of LPL, HSL & lipolysis in human adipose tissue. Diabetes 51 (2002) 1493-1498
8. McTernan P.G., McTernan C.L., Chetty R., Jenner K., Fisher F.M., Lauer M.N., et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87 (2002) 2407-2410
9. McTernan C.L., McTernan P.G., Harte A.L., Levick P., Barnett A.H., and Kumar S. Resistin-the link between central obesity and type 2 diabetes. Lancet 35 (2002) 46-47
10. Fisher M., McTernan P.G., Valsamakis G., Harte A.L., Anwar A.J., Chetty R., et al. Changes in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 34 (2002) 650-654
11. Katrinchak C., and Fritz K. Clinical implications of C-reactive protein as predictor of vascular risk. J Am Acad Nurse Pract 19 (2007) 335-340
12. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
13. Yildiz B., and Haznedaroglu I.C. Rethinking leptin and insulin action: therapeutic opportunities for diabetes. Int J Biochem Cell Biol 38 (2006) 820-830
14. Steppan C.M., Bailley S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
15. Rangwala S.M., Rich A.S., Rhoades B., Shapiro J.S., Obici S., Rossetti L., and Lazar M.A. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53 (2004) 1937-1941
16. Janke J., Engeli S., Gorzelniak K., Luft F.C., and Sharma A.M. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 10 (2002) 1-5
17. Savage D.B., Sewter C.P., Klenk E.S., Segal D.G., Vidal-Puig A., Considine R.V., et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator activated receptor-gamma action in humans. Diabetes 50 (2001) 2199-2202
18. Nagaev I., and Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscles. Biochem Biophys Res Commun 285 (2001) 561-564
19. Graveleau C., Zaha V.G., Mohajer A., Banerjee R.R., Dudley-Rucker N., Steppan C.M., et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 280 (2005) 31679-31685
20. Al-Daghri N., Chetty R., McTernan P.G., Al-Rubean K., Al-Attas O., Jones A.F., et al. Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in Saudi population. Cardiovasc Diabetol (2005) 4-10
21. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
22. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
23. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratle R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
24. Funahashi T., Nakamura T., Shimomura I., Maeda K., Kuriyama H., Takahashi M., et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38 (1999) 202-206
25. Matsuzawa Y., Funahashi T., and Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 892 (1999) 146-154
26. Yokoyama H., Emoto M., Mori K., Araki T., Teramura M., Koyama H., et al. Plasma adiponectin level is associated with insulin-stimulated non-oxidative glucose disposal. J Clin Endocrinol Metab 91 (2006) 290-294
27. Yang W.S., Lee W.J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.L., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
28. Okamoto Y., Arita Y., Nishida M., Muraguchi M., Ouchi N., Takahashi M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2000) 47-50
29. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
30. Matsuda M., Kawasaki F., Inoue H., Kanda Y., Yamada Y., Harada Y., et al. Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Res Clin Pract 66 (2004) S121-S123
31. Taylor A.K., Lueken S.A., Libanati C., and Baylink D.J. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 20 (1994) 589-607
32. Matthews D.R., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
33. Wabitsch M., Blum W.F., Muche R., Braun M., Hube F., Rascher W., et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest 100 (1997) 808-813
34. Machinal F., Dieudonne M.N., Leneveu M.C., Pecquery R., and Giudicelli Y. Invivo and in vitro ob gene expression and leptin secretion in rat adipocytes: evidence for a regional specific regulation by sex steroid hormones. Endocrinology 140 (1999) 1567-1574
35. Baratta M. Leptin: from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit 8 (2002) RA282-RA292
36. Kieffer T.J., and Habener J.F. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 278 (2000) E1-E14
37. Segal K.R., Landt M., and Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 45 (1996) 988-991
38. Wasim H., Al-Daghri N., Chetty R., McTernan P.G., Barnett A.H., and Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol (2006) 5-10
39. Janowska J., Zahorska-Markiewicz B., and Olszanecka-Glinianowicz M. Relationship between serum resistin concentrations and pro-inflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism 55 (2006) 1495-1499
40. Al-Harithy R.N., and Al-Ghamdi S. Serum resistin, adiposity and insulin resistance in Saudi women with type2 diabetes mellitus. Ann Saudi Med 25 (2005) 283-287
41. Liu G.L., Fu X.H., Jiang L.H., Ma X.C., and Yang J.Y. Serum resistin concentration and insulin resistance in obese children. Zhonghua Er Ke Za Zhi (2006) 44114-44117
42. Kusminski C.M., McTernan P.G., and Kumar S. Role of resistin in obesity, insulin resistance and type 2 diabetes. Clin Sci 109 (2005) 00-10
43. Nilsson P.M., Engstrom G., Hedblad B., Frystyk J., Persson M.M., Berglund G., et al. Plasma adiponectin levels in relation to carotid intima thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 26 (2006) 2758-2762
44. Koenig W., Khuseyinova N., Baumert J., Meisinger C., and Lowel H. Serum concentrations of adiponectin and risk of type2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from South Germany. J Am Coll Cardiol 48 (2006) 1369-1377
45. Inoue M., Yano M., Yamakado M., Maehata E., and Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 55 (2006) 1248-1254
46. Koebnick C., Wagner K., Garcia A.L., Gruendel S., Lahmann P.H., Weickert M.O., et al. Increase in serum resistin during weight loss in overweight subjects is related to lipid metabolism. Int J Obes 30 (2006) 1097-1103
47. Yannakoulia M., Yiannakouris N., Bluhler S., Matalas A.L., Klimis-Zacas D., and Mantozoros C.S. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88 (2003) 1730-1736
48. Pfutzner A., and Forst T. High-sensitivity C-reactive protein as a cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8 (2006) 28-36
49. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939